Daily FNArena News - Small Caps

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results

Tim Boreham highlights the prospects for cancer treatment biotech Imugene

Despite higher interest rates, Autosports Group is seeing no easing in demand for luxury cars, providing solid revenue growth guidance at its AGM

Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions

Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising

Already enthusiastic analysts have lifted their enthusiasm regarding Dropsuite’s outlook following impressive third quarter results

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports

The New Criterion’s Tim Boreham navigates the choppy seas of a fraught Australian seafood-farming market

While interim results for Sigma Healthcare met expectations, brokers see margin upside from improved operating leverage

Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030